RR-215

N/A

Report date: 2024/03/05 15:34:31
NME

Base Information

Drug NameRR-215
Drug Alias NameRR-215
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsInflammationPancreatic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaDiscontinued
Originator CompaniesAccro Bioscience (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAccro Bioscience (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsInflammationPancreatic NeoplasmsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A